News & Events

Learn about what's new with CMC Biologics

CPhI Japan 2017, April 19 - 21, Tokyo, Japan

Events


February 28 - March 2, 2017 
CPhI Japan 2017, Big Sight Exhibition Centre, Tokyo


cphi_japan_logo.jpgJoin CMC Biologics at CPhI Japan, located at Big Sight Exhibition Centre, Tokyo, Japan. Visit us and learn about our world-class CDMO capabilities, and discuss your challenges with our team.

BIO Korea 2017, April 12 - 14, Seoul, South Korea

Events


February 28 - March 2, 2017 
BIO Korea 2017, Seoul, South Korea



sBio-Korea.pngJoin CMC Biologics at BIO Korea, April 12 - 14, 2017, located at COEX in Seoul South Korea. Visit us and learn about our world-class CDMO capabilities, and discuss your challenges with our team.

BIO-Europe Spring 2017, March 20 - 22, Barcelona, Spain

Events


March 20-22, 2017 
WADC 2017, Berlin, Gemany


bio-europe-spring-2017-barcelona.jpgJoin CMC Biologics, PROVEOTM and more than 2,400 of your peers at BIO-Europe Spring 2017, March 20-22, in Barcelona, Spain.

Join us at the premier springtime partnering conference, bringing together a “whoʼs who” from biotech, pharma and finance in Europe's most innovative biopharma clusters. Meet our team and learn about our world-class CDMO capabilities, and our PROVEO Alliance for providing a complete ADC solution.

Contact us to set up a meeting with our team, and to learn more.

CMC Biologics and Genexine Announce Manufacturing Agreement for Genexine's Human Growth Hormone Drug, GX-H9

News

----_Genexine_Logo.jpgBOTHELL, Washington, U.S.A., and SEONGNAM, Republic of Korea, February 21, 2017 - CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Genexine, Inc. (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of Genexine’s GX-H9.

DCAT 2017, March 20 - 23, New York, NY

Events


March 20-23, 2017 
DCAT 2017, New York, NYMeet-Us-Picture-Icon-DCAT-2017.png

Join CMC Biologics in New York for the Drug, Chemical & Associated Technologies Association (DCAT) Week 2017. Meet our team and learn about our world-class CDMO capabilities, and our PROVEO Alliance for providing the complete ADC solution.

Contact us to set up a meeting with our team, and to learn more.

CMC Biologics Enters into Manufacturing Agreement with CytoDyn

News

Agreement covers process development and manufacture of CytoDyn’s PRO 140

 

Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– February 15, 2017 –CMC Biologics, a
 global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and CytoDyn Inc., a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection, announced today they have entered into an agreement for the process development and commercial manufacture of CytoDyn’s PRO 140.